-
Mashup Score: 2Disease‐modifying antirheumatic drugs and risk of thyroxine‐treated autoimmune thyroid disease in patients with rheumatoid arthritis - 5 month(s) ago
Background Autoimmune thyroid disease (AITD) and rheumatoid arthritis (RA) share a genetic background, and the prevalence of AITD in RA patients is increased. Whereas immunomodulatory treatments are…
Source: onlinelibrary.wiley.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 23Acute longus colli calcific tendinitis - 5 month(s) agoSource: link.springer.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 60Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping - 5 month(s) ago
Objective Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases (AIRDs) is essential towards personalised medicine. Methods We conducted large-scale and cohort-wide immunophenotyping of 46 peripheral immune cells using Human Immunology Protocol of comprehensive 8-colour flow cytometric analysis. Dataset consisted of >1000 Japanese patients of 11 AIRDs with deep clinical information registered at the FLOW study, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In-depth clinical and immunological characterisation was conducted for the identified RA patient clusters, including associations of inborn human genetics represented by Polygenic Risk Score (PRS). Results Multimodal clustering of immunophenotypes deciphered underlying disease-cell type network in immune cell, disease and patient cluster resolutions. This provided immune cell type specificity shared or distinct across AIRDs, such as close immunological network between m
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 19Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort - 5 month(s) ago
Objectives To study long-term (up to 20-year) mortality of two treat-to-target trial cohorts in undifferentiated arthritis (UA) and early rheumatoid arthritis (RA). Methods The BeSt (BehandelStrategieën) study (n=508, early RA) was performed between 2000 and 2012. For 10 years, patients were treated-to-target disease activity score (DAS)≤2.4. The Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease (IMPROVED) study (n=610, early RA/UA) was performed between 2007 and 2015. For 5 years, patients were treated-to-target DAS<1.6. Vital status of BeSt/IMPROVED participants was assessed up to and including 31 December 2021. Standardised mortality ratios (SMRs) were calculated. Stratified analyses for anticitrullinated protein antibody (ACPA) and smoking status were performed. Death causes and the potential effect of disease activity during the trial period on late mortality were assessed. Results Excess mortality was found in both BeSt (SMR 1.32, 95
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 2Limited Diagnostic and Prognostic Value of Routine Radiographs in Newly Presenting Arthritis Suspected of Rheumatoid Arthritis: A Retrospective Study - 6 month(s) ago
Objective Current recommendations suggest that patients with newly presenting arthritis suspected of Rheumatoid Arthritis (RA) should undergo routine radiographs of hands and feet (X-HF) as the pres…
Categories: General Medicine News, RheumatologyTweet-
Retrospective study(2016-2019) of referred newly, suspected (#RA) pts found no value in initial Xrays. Only 32/724 patients (4.4%) had RA like erosions, with Erosions leading to a Dx in only 2 pts (0.3%) & changed prognostic classification in 3 pts (0.4%) https://t.co/fi48WiBgIc https://t.co/skObArXYr6
-
-
Mashup Score: 0
Objectives This study aims to evaluate non-melanoma skin cancer (NMSC) risk associated with abatacept treatment for rheumatoid arthritis (RA). Methods This evaluation included 16 abatacept RA clinical trials and 6 observational studies. NMSC incidence rates (IRs)/1000 patient-years (p-y) of exposure were compared between patients treated with abatacept versus placebo, conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) and other biological/targeted synthetic (b/ts)DMARDs. For observational studies, a random-effects model was used to pool rate ratios (RRs). Results ~49 000 patients receiving abatacept were analysed from clinical trials (~7000) and observational studies (~42 000). In randomised trials (n=4138; median abatacept exposure, 12 (range 2–30) months), NMSC IRs (95% CIs) were not significantly different for abatacept (6.0 (3.3 to 10.0)) and placebo (4.0 (1.3 to 9.3)) and remained stable throughout the long-term, open-label period (median cumulative exposur
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 3
Rheumatoid arthritis mortality has decreased globally over the past three decades. Global age-standardised prevalence rate and YLDs have increased over the same period, and the number of cases is projected to continue to increase to the year 2050. Improved access to early diagnosis and treatment of rheumatoid arthritis globally is required to reduce the future burden of the disease.
Source: www.thelancet.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0HSV and RSV Update | RheumNow - 7 month(s) ago
Dr. Kevin Winthrop provides an HSV and RSV update for rheumatology as part of RheumNow’s Hard Decisions in RA campaign. Eight debates and perspectives on Hard Decisions in RA now available.
Source: rheumnow.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Prevalence, Severity and Measures of Anxiety in Rheumatoid Arthritis: A Systematic Review - 7 month(s) ago
Objectives Many studies have reported high rates of anxiety in adults with Rheumatoid Arthritis (RA). The aim of this systematic review was to examine those findings and determine the overall preval…
Categories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 5Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis - 7 month(s) ago
Objectives To evaluate which American College of Rheumatology (ACR) response definition (ACR20, 50 or 70) should primarily be used for efficacy claims in future drug approval trials of rheumatoid arthritis (RA). Methods We systematically searched EMBASE, Medline and the Cochrane Library for randomised controlled RA drug approval trials of biological and targeted synthetic disease-modifying antirheumatic drugs (DMARDs). We included full-text articles reporting ACR response rates for multiple time points over a 24-week placebo-controlled period and visualised normalised response trajectories over time in different patient populations. Using mixed-effect logistic regression, we calculated the proportion of ACR responders per outcome and time point, and compared the discriminant validity of these metrics at multiple time points. Results We screened 12 680 records and included 45 in the final analysis. Discriminative capacity of the ACR20 was high across all time points, whereas ACR50 and A
Source: ard.bmj.comCategories: Latest Headlines, RheumatologyTweet-
Is ACR20/50/70 still the right response definition for drug approval trials of #RA? 🔹 systemic literature review of 45 records ✔️ discriminative capacity of ACR20 high across all time points ✔️ ACR50 and ACR70 highest discrimination at later time points https://t.co/ys09coRvlK https://t.co/ZFtCY7Mkux
-
Swedish national cohort study cohort study suggests #RA pts at incr risk for Autoimmune thyroid Dz, but decreases after RA Dx & Rx. n=13,731 RA vs 63,201 matched pop. controls. Lower rates AITD w/ biologics & TNFi (HR 0.54, 0.67) https://t.co/ZfputgDJQE https://t.co/Z1r0eGFcX9